Although there appears to be a decline in the mortality associated with the acute respiratory distress syndrome (ARDS), from 60% to 40% over the past decade 1 , the figure still remains high. As can be predicted from the large number of predisposing factors for ARDS, there has been no single therapeutic breakthrough.
In addition to the previously described modalities of therapy 1 , there has been recent interest in the use of inhaled selective pulmonary vasodilators (SPV) in ARDS. Selective pulmonary vasodilation by the inhaled route has the theoretical advantages of reduction in shunt fraction ( . Q s / . Q t ) coupled with a reduction in pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP). If the agent used is a true SPV the above effects are accomplished without systemic hypotension and result in an improvement of ventilation perfusion ( . V/ . Q) matching in the lung. The net effect is an improvement in oxygenation and reduction in PAP.
The two agents which have gained currency as SPVs are nitric oxide (NO) [2] [3] [4] [5] [6] [7] [8] and inhaled aerosolized prostacyclin (IAP) [9] [10] [11] [12] [13] [14] [15] . NO was the first agent available and has been shown unequivocally to improve oxygenation in very low concentrations 5, 8 and to reduce PAP at higher doses [2] [3] [4] in patients with ARDS. However, an improved outcome following NO administration has not yet been shown in clinical trials.
The first use of IAP was described in 1984 when it was administered to five volunteers 16 . Further work with IAP, including small series in dogs 11 and in humans 13 , appeared in 1993. Subsequent reports of IAP usage have been sparse, but include a series of twelve patients with pneumonia 12 , isolated case reports 15, 17, 18 , correspondence 10 and some animal work 14 . There have been two animal trials comparing the effects of NO and IAP in the same subjects 11, 14 . These trials show the efficacy of IAP to be comparable to NO. Pappert and co-workers have reported a series of three children with ARDS where IAP was compared to NO 19 . To the authors' knowledge, there have been no adult comparative trials.
The current study was devised to compare the effects of previously-proven clinically useful doses of NO (10 parts per million (ppm)) 7, 8 and IAP (50 ng/kg/min) 12, 13 in patients with ARDS. This pilot study, if the results were favourable, would allow for the further exploration of the advantages of the use of IAP over NO for hypoxaemia and pulmonary hypertension (i.e. ease of administration and less capital costs for delivery and monitoring of inspired gas concentrations).
MATERIALS AND METHODS
Institutional Human Rights Committee and Clinical Drug Trials Committee approval was obtained and informed consent sought (from patient surrogates) prior to enrolling patients in the study.
Inclusion/Exclusion Criteria
Patients considered for study enrolment were required to be mechanically ventilated (IPPV) in the Intensive Care Unit (ICU) with ARDS as defined by the American-European consensus conference on ARDS 20 , with a lung injury score (LIS) 21 of greater than 2. Cardiogenic pulmonary oedema (pulmonary capillary wedge pressure (PCWP) >18 mmHg) and pneumonia (no bacteria on bronchoalveolar lavage (BAL) performed the day prior to enrolment) were excluded prior to enrolment in the trial. Patients within the first 24 hours of admission to ICU or who were haemodynamically unstable, requiring frequent changes in inotrope and vasopressor requirements, were not deemed suitable for the trial. No intravenous volume replacement therapy, changes in inotrope/vasopressor infusion rates, changes in minute ventilation ( . V m ) or fractional inspired oxygen concentration (FiO 2 ) were permitted during the two-hour study period. If changes in any of these parameters were required the patient was excluded from the trial.
Study design
Patients meeting the above criteria were studied for a two-hour period to minimize other temporal variables. Each patient was exposed to 30 minutes of either NO (10 ppm) or IAP (50 ng/kg/min) in random order. Each treatment period was followed by a 60-minute "rest" period to allow for the elimination of the study agent. The patient was then exposed to the other agent for 30 minutes (i.e. within-patient controlled crossover design). No changes in vasopressor/inotrope infusion rates, FiO 2 or . V m occurred during this two-hour period. The patient was maintained in the supine position throughout the study period.
NO (BOC Medical Gases, Chatsworth, N.S.W., Australia) 10 ppm was delivered via the mechanical ventilator (Servo C, Siemens-Elema AB, Sweden) using a technique previously validated 6 . IAP was administered using the set-up depicted in Figure 1 . Epoprostenol sodium 500 µg (Flolan ® , GlaxoWellcome Australia Ltd, Boronia, Victoria, Australia) dissolved in 50 ml of glycine diluent was pumped at a constant rate by syringe pump A into the nebulizer bowl C (Airlife, Misty-Neb, Baxter Healthcare, California, U.S.A.), placed 5 cm from the proximal end of the endotracheal tube to minimize "rainout" of the aerosol. The inspired gas in both sections of the trial was warmed and humidified using a Fisher and Paykel model 328 humidifier (Fisher and Paykel Healthcare Pty Ltd, Ringwood, Victoria, Australia) to reduce aerosol condensation. The nebulizer was driven by a 6 l/min flow of air/oxygen from flowmeter D at the same FiO 2 as the inspired gas being delivered by the mechanical ventilator. The nebulizer bowl was primed with 2 ml of the epoprostenol solution prior to commencing the constant infusion which would deliver a dose of 50 ng/kg/min to the nebulizer bowl for aerosolization into the inspired gas. The brand of nebulizer used produces epoprostenol diluent particles with a mass median diameter of 5.08 µm, with 51% of particles being smaller than 5.17 µm, as measured by a laser particle analyser (Malvern Laser Particle Analyser Model MS 20, Malvern Instruments Ltd., Malvern, Worcs., U.K.). Together with the physiological response demonstrated, this leads the authors to infer the distal site of deposition of the IAP. It was not possible to measure the actual mass of IAP deposited in alveoli or the fraction vented in the expired gases.
Measurements
On entry to the trial all patients were monitored with continuous electrocardiography (ECG), pulse oximetry (SpO 2 ) and invasive arterial and pulmonary artery (PA) pressures. Cardiac output was measured intermittently by thermodilution via the PA flowdirected, balloon-tipped catheter. Blood samples were drawn from the arterial and PA catheters as appropriate immediately prior to and at the end of each 30 minute exposure to the SPV (either NO 10 ppm or IAP 50 ng/kg/min) and immediately analysed for the following: * arterial blood gases (ABG) and mixed venous blood gases using an ABL 520 blood gas analyser (Radiometer, Copenhagen, Denmark), at 37 degrees centigrade (°C), * arterial methaemoglobin (metHb) levels utilizing the co-oximeter of the ABL 520 analyser. Invasive arterial and pulmonary artery pressures and cardiac output were measured at the same intervals-immediately prior to exposure to the SPV and on termination of exposure to the SPV (after 30 minutes).
Alveolar-arterial oxygen partial pressure gradient (A-aDO 2 ) and . Q s / . Q t were then calculated using standard equations.
Statistical analysis
The paired data from the five patients entered into the trial were analysed using Wilcoxon Matched Pairs Signed-Rank test. A P value of <0.05 was considered significant.
RESULTS
The patient demographic data are shown in Table 1 .
Mean arterial pressure (MAP), cardiac output (CO), heart rate (HR), central venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP) did not change significantly with exposure to either of the SPVs (Table 2 ). MetHb levels were obtained for four of the five patients. There was no significant increase in metHb levels after exposure to either SPV. Qt). A=pre-nitric oxide; B=post-nitric oxide; C=pre-inhaled prostacyclin; D=post-inhaled prostacyclin.
A-aDO 2 ( Figure 4 ) decreased in all patients exposed to IAP (from C to D, P=0.01) and in three patients exposed to NO. The increase in measured arterial partial pressure of oxygen (P a O 2 ) post IAP therapy approached statistical significance (P=0.06).
DISCUSSION
In the five patients described above there were no haemodynamic consequences of exposure to either NO or IAP, except for a reduction in MPAP, as would be expected after exposure to a pulmonary vasodilator. This is in keeping with previous studies where the lack of systemic effect after exposure to NO 2-8 and IAP 9,11,12,13 has been described. This is due to the short half-lives of the agents involved-seconds in the case of NO and minutes in the case of IAP. IAP would be more likely to produce systemic hypotension due to its longer half-life if delivered in high doses. In addition there is the theoretical risk that if sufficiently high doses of IAP are administered, prostacyclin may reach the venous circulation and result in an increase in right-to-left shunting through the pulmonary circulation and a worsening of oxygenation (i.e. act as an intravenously-delivered vasodilator downstream). This effect was however not demonstrated in this series, nor in a patient to whom we administered doses of IAP as high as 200 ng/kg/min 17 . The reduction in A-aDO 2 and . Q s / . Q t in most patients exposed to these two SPVs confirms an improvement in oxygenation. This effect occurred at doses of NO and IAP which have previously been shown to be clinically useful, but which have to date not been compared to each other in adult subjects with ARDS. The increase in these parameters in two patients in the NO group is not readily explained. A larger study would determine the significance of this finding (i.e. chance vs consistent finding).
A concern with the use of IAP is the high alkalinity (pH = 10.5 ± 0.3) of the buffer in which the epoprostenol is diluted prior to aerosolization. To the authors' knowledge there are no toxicological studies relating to the effect of this buffer on the respiratory mucosa of humans and as such we have limited this therapy to patients with severe hypoxaemia in whom NO would otherwise have been considered a modality of therapy. This, together with the strict inclusion criteria we adopted for this study, has limited the size of the current study, as is the case with most other series investigating IAP as an SPV 12, 13, 19 . Short-term exposure to the two agents used in this study did not result in a marked increase in metHb levels in the four patients from whom measurements were obtained. The area of the toxicology of these SPVs, in particular that of IAP, also requires further elucidation.
The advantage of IAP in terms of ease of administration, together with the promising results in patients with ARDS in this as well as previous series [11] [12] [13] would encourage the authors to further investigate IAP as a selective pulmonary vasodilator of some potential. IAP in this group of patients appears to be at least as effective as NO in the doses selected. However, the optimal dose of IAP required to improve oxygenation is not known. A single doseresponse curve obtained in a patient with severe ARDS suggests a dose of 30-40 ng/kg/min is as effective as a dose of 50 ng/kg/min 18 . It is therefore possible that an equivalent effect to low dose NO (10 ppm or less) may be obtained at somewhat lower doses of IAP. The actual mass of epoprostenol deposited in ventilated alveoli as a fraction of the mass aerosolized into the ventilator circuit (i.e. the effective dose) would be less than the delivered doses stated above. Previous authors estimate that as little as 10% of nebulized drug may be deposited in the alveoli of ventilated patients 22, 23 . The cost of IAP therapy is approximately $50 to $100 per hour in the adult patient. This will be a factor in the long-term place of this agent in the therapy of conditions such as ARDS where prolonged treatment with a SPV may be required. Despite this, IAP appears to be an effective SPV which is simple to administer and is worthy of further investigation.
